產(chǎn)品詳情
簡單介紹：
Anti-NALP12抗體產(chǎn)品質(zhì)量穩(wěn)定，實驗效果明顯，貨期快，價格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實驗抗體。Anti-NALP12抗體用于**組化實驗,WB實驗,相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-NALP12
Cat. Number:
Anti-NALP12抗體KL-6864R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
May mediate activation of CASP1 via ASC and promote activation of NF-kappa-B via IKK.NALP proteins are cytoplasmic proteins that form a subfamily within the larger CATERPILLER family and are thought to play a Anti-NALP12抗體crucial role in cell proliferation and reproduction. Like all other NALP family members, NALP12, also known as Monarch-1, has a C-terminal leucine-rich repeat (LRR) region, an N-terminal Pyrin domain (PYD) followed by a NACHT domain, and a NACHT-associated domain. NALP12 is thought to act as an attenuating factor of inflammation by suppressing inflammatory responses such as NF-kB activation by TLR-signaling molecules MyD88, IRAK-1, TRAF6 and RIPK1 in activated monocytes. Recent evidence suggests that mutations in NALP12 result in hereditary periodic fever syndromes.
Also known as:
CLR19.3; FCAS2; Monarch 1;Anti-NALP12抗體 Monarch-1; NACHT, leucine rich repeat and PYD containing 12; NACHT, LRR and PYD containing protein 12; NACHT, LRR and PYD domains-containing protein 12; NAL12_HUMAN; NLR family, pyrin domain containing 12; NLRP12; Nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 12; PAN6; PYPAF7; PYRIN containing APAF1 like protein 7; PYRIN-containing APAF1-like protein 7; Regulated by nitric oxide; RNO; RNO2.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Anti-NALP12抗體Rat, Dog, Pig, Cow, Horse, Rabbit, Sheep, .
●
Immunogen: KLH conjugated synthetic peptide derived from human NALP12.
●
Predicted Molecular Weight: 117kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
Not yet tested in other applications. Anti-NALP12抗體
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications. Anti-NALP12抗體
Optimal working dilutions must be determined by the end user.
